open access

Vol 68, No 11 (2010)
Original articles
Published online: 2010-11-24
Submitted: 2012-12-28
Get Citation

Serum paraoxonase 1 activity in women with metabolic syndrome

Hale Yilmaz, Nurten Sayar, Mehmet Yilmaz, Ufuk Gurkan, Cenk Sesal, Rodi Tosu, Nazmiye Cakmak, Betul Erer, Dilaver Oz, Figen Ciloglu, Osman Bolca
Kardiol Pol 2010;68(11):1219-1224.

open access

Vol 68, No 11 (2010)
Original articles
Published online: 2010-11-24
Submitted: 2012-12-28

Abstract


Background: Metabolic syndrome (MetS) is a leading risk factor for coronary artery disease (CAD) in women. Reduced paraoxonase 1 (PON1) activity may play a role in the pathogenesis of atherosclerosis through increased susceptibility to lipid peroxidation in patients with MetS.
Aim: To examine whether there is a relationship between serum PON1 activity and MetS in women.
Method: The study group consisted of 54 women with MetS. The NCEP ATP III guidelines were used to define MetS. The control group consisted of 65 women without MetS and CAD. All patients from the MetS group underwent coronary angiography.
Results: The PON1 activity and salt-stimulated PON1 activity were not significantly altered in women with MetS when compared to controls (p = 0.902, p = 0.877, respectively). There was no significant difference in PON1 activity (p = 0.159), and salt-stimulated PON1 activity (p = 0.139) between diabetics and non-diabetics. In the MetS group, patients with CAD (n = 16) had significantly reduced PON1 activity and salt-stimulated PON1 activity compared to MetS patients without CAD (p = 0.008 and p = 0.004, respectively).
Conclusions: Serum PON1 activity is significantly reduced in women with CAD and MetS. MetS per se does not alter serum PON1 activities.
Kardiol Pol 2010; 68, 11: 1219-1224

Abstract


Background: Metabolic syndrome (MetS) is a leading risk factor for coronary artery disease (CAD) in women. Reduced paraoxonase 1 (PON1) activity may play a role in the pathogenesis of atherosclerosis through increased susceptibility to lipid peroxidation in patients with MetS.
Aim: To examine whether there is a relationship between serum PON1 activity and MetS in women.
Method: The study group consisted of 54 women with MetS. The NCEP ATP III guidelines were used to define MetS. The control group consisted of 65 women without MetS and CAD. All patients from the MetS group underwent coronary angiography.
Results: The PON1 activity and salt-stimulated PON1 activity were not significantly altered in women with MetS when compared to controls (p = 0.902, p = 0.877, respectively). There was no significant difference in PON1 activity (p = 0.159), and salt-stimulated PON1 activity (p = 0.139) between diabetics and non-diabetics. In the MetS group, patients with CAD (n = 16) had significantly reduced PON1 activity and salt-stimulated PON1 activity compared to MetS patients without CAD (p = 0.008 and p = 0.004, respectively).
Conclusions: Serum PON1 activity is significantly reduced in women with CAD and MetS. MetS per se does not alter serum PON1 activities.
Kardiol Pol 2010; 68, 11: 1219-1224
Get Citation

Keywords

paraoxonase activity; metabolic syndrome; coronary artery disease

About this article
Title

Serum paraoxonase 1 activity in women with metabolic syndrome

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 68, No 11 (2010)

Pages

1219-1224

Published online

2010-11-24

Bibliographic record

Kardiol Pol 2010;68(11):1219-1224.

Keywords

paraoxonase activity
metabolic syndrome
coronary artery disease

Authors

Hale Yilmaz
Nurten Sayar
Mehmet Yilmaz
Ufuk Gurkan
Cenk Sesal
Rodi Tosu
Nazmiye Cakmak
Betul Erer
Dilaver Oz
Figen Ciloglu
Osman Bolca

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl